ネクセラファーマ株式会社 Q3 FY2026 earnings call

• Profitability & Growth: Nexera is now profitable, achieving core operating profit ahead of full-year guidance. Nine-month revenue rose 27% to 27.7 billion yen.
• Japan Commercial Business: Pivlas sales grew 10% to 9.9 billion yen. Qvivik sales surged 43% to 4.5 billion yen. Shionogi revised its sales forecast upward, supporting continued growth.
• New Product Launches: Leucerostat was added as the fourth product in Japan for Fabry disease. Vamorolone is on track for approval in Japan and Korea in 2028, leveraging existing commercial synergies.
• UK R&D & Partnerships: Seven molecules are in partner clinical trials, with one in Phase 3. Partnered revenue jumped 63% to 13.3 billion yen. Potential milestones exceed $4.5 billion USD.
• Cost Control: Core R&D costs decreased by 20% and SG&A by 11%, contributing to improved margins.
• Strategic Vision: Reiterated targets for 2030: >50 billion yen revenue, >30% operating margin, and at least five products in Japan.

Total revenue increased 27% year-over-year to 27.7 billion yen. Core operating profit reached 9.8 billion yen, marking a transition from a loss in the prior period to profitability. The commercial segment (medicines in Japan) generated 14.4 billion yen in sales, contributing approximately 52% of total revenue, with Pivlas accounting for 9.9 billion yen and Qvivik for 4.5 billion yen. The platform/partnership segment contributed 13.3 billion yen in milestone and partnership revenue (approximately 48% of total revenue), driven by advancements from partners including Neurocrine, Lilly, AbbVie, and Sintesa.

• Full-Year Profitability: Management expects to remain profitable for the full fiscal year, having already exceeded core operating profit guidance at the nine-month mark.
• Revenue Trajectory: Maintains long-term target of more than 50 billion Japanese yen in revenue by 2030, implying ~10% annual growth.
• Margin Expansion: Targets an operating margin above 30% by 2030 and around 40% by 2035.
• Near-Term Milestones: Expects continued milestone payments from partners in FY2027 and potential new partnerships closing in late FY2026 or early FY2027.

• Milestone Volatility: Platform business profits are heavily dependent on partner milestones, which are difficult to control and may cause earnings volatility.
• Supply Chain Lags: Product supply planning creates a time lag between market demand spikes and shipment volumes, potentially causing short-term fluctuations in royalty calculations.
• Partnership Execution: Success relies on the timely advancement of partner clinical programs (e.g., Phase 3 data for Directvidine and ORX750); delays could impact future royalty streams.
• Competitive Landscape: Competitors like Takeda have launched first-in-class orexin antagonists, though Nexera believes its differentiated profile offers advantages.

Q: Can Nexera sustain profitability next fiscal year given milestone timing risks? / A: CFO Nomura stated they cannot guarantee stability due to milestone timing but expressed personal confidence in generating profit, citing upcoming royalties and commercial growth. CEO Cargill clarified that the discovery platform is not a 'drag' but a value generator, and multiple near-term partnerships are expected to support earnings.